← All trials
NCT07047014
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2025
- Primary completion
- Mar 30, 2027
- Completion date
- Jun 30, 2027
- First posted
- Jul 2, 2025
- Last posted
- Nov 19, 2025
- Enrollment
- 596
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Zhejiang UniversityCollaborator
- Zhejiang UniversityOfficial
- Capital Medical UniversitySponsor investigator
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.